CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection as Monotherapy or in Combination With Azacitidine or Venetoclax in Patients With Relapsed/Refractory Myeloid or B-cell Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05107856
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:40:00.066098+00:00
Published At: 2024-01-31T00:00:00+00:00
Record Updated At: 2024-01-31
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Acute Myeloid Leukemia", "B-cell Non-Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia", "Chronic Myelomonocytic Leukemia", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Myelodysplastic Syndromes", "Myeloproliferative Neoplasm", "Small Lymphocytic Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-01-31"
protocolSection.identificationModule.nctId: "NCT05107856"
protocolSection.identificationModule.officialTitle: "A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection as Monotherapy or in Combination With Azacitidine or Venetoclax in Patients With Relapsed/Refractory Myeloid or B-cell Malignancies"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.